secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001437749-25-009723
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q4 GAAP net loss widens to $19.4M; cash boosted to $118M on warrant exercises
--------------------------------------------------------------------------------

- GAAP net loss of $19.4M in Q4 2024 vs $11.9M a year ago; full-year loss $53.6M vs $42.2M.
- Cash and equivalents $118.0M as of Dec 31, 2024, up from $44.4M a year ago, driven by $47.9M in warrant proceeds.
- Non-GAAP net loss Q4 $10.4M vs $8.3M; full-year $36.9M vs $33.8M; costs rose on stock comp and legal settlement.
- Advanced soft tissue ablation pilot at 8 U.S. centers; expects U.S. thyroid clinical trial mid-2025.
- Treated 30 patients in European AF feasibility study for surgical clamp; over 80 patients in catheter study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925009723/0001437749-25-009723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925009723/plse20241119_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer